INTRODUCTION
Growth arrest-specific gene 6 (Gas6) was discovered, because its expresssion is upregulated in fibroblasts under growth-arrest conditions 1, 2 . This factor exerts pleiotropic functions in health and disease: it amplifies platelet aggregation during thrombus formation 3, 4 , enhances erythropoiesis 5 and increases leukocyte extravasation in inflammatory conditions 6 , amongst other functions 7, 8 . Gas6 binds to the TAM family of receptor tyrosine kinases (TAMRs), which consists of Tyro3 (Sky/Rse), Axl (Ufo/Ark) and Mer (Eyk), though the binding affinity of this ligand differs for each receptor (Axl>Tyro3>>Mer) 9, 10 . TAMRs, in particular Axl, have transforming properties. Indeed, overexpression of a truncated version of Axl in premalignant cells is sufficient to induce tumors in mice 11 . Axl is also highly expressed in human tumor cells in vitro [12] [13] [14] [15] , as well as in a large variety of primary human cancers, including leukemia 16 However, little is known about the role of Gas6 in cancer. Gas6 is overexpressed in human ovarian, endometrial, gastric, thyroid and glioblastoma tumors 17, [20] [21] [22] [23] . In those studies, expression of Gas6 was detected in tumor cells, endothelial cells and astrocytes 20, 21, 23, 24 , but expression of Gas6 in tumor-infiltrated leukocytes has not been studied so far. Gas6 promotes proliferation and survival of different cancer cell lines, including prostate and melanoma tumor cells 13, 14 . Interestingly, when glioma tumors co-express high levels of Axl and Gas6, survival of cancer patients is shortened 21 . Inhibition of Gas6 by a soluble Axl trap in vitro or a dominant negative variant of Axl in tumor cells in vivo suppresses proliferation and invasion of cancer cells, thereby prolonging survival of tumorbearing mice 17, 25 .
In general, little is known about the role of Gas6 in the tumor stroma, especially
For personal use only. on March 31, 2017. by guest www.bloodjournal.org From about its expression in tumor-inflaming leukocytes, which play a key role in cancer progression 26, 27 . Intratumoral leukocyte infiltrates vary in size, composition and distribution and, in most, but not in all instances, they are believed to promote tumor progression via several mechanisms, including secretion of growth factors, pro-angiogenic cytokines and proteases 26 . Tumor-associated macrophages (TAMs) are prominent components of leukocyte infiltrates and are frequently polarized to an M2 phenotype, characterized by growth promoting, pro-angiogenic and immunosuppressive properties [26] [27] [28] . As a result, the presence of high numbers of macrophages in tumors often confers a negative prognosis for cancer patients 28 . However, TAMs exhibit a remarkable level of complexity and can also be skewed towards an M1-polarized phenotype with a potential to kill tumor cells via phagocytosis or to activate anti-tumoral immune effector cells 28 .
Because Gas6 is present in hematopoietic cells [29] [30] [31] , we explored whether stromal, and, in particular, macrophage-derived Gas6 might play a role in tumor biology and therefore implanted WT tumors in Gas6 -/-mice. Here, we unravel a previously unknown mechanism whereby tumors educate infiltrating leukocytes to upregulate Gas6 and as such promote their growth.
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EXPERIMENTAL METHODS
Note: For further details, we refer to the supplement (supplemental methods).
ANIMALS AND SYNGENEIC TUMOR MODELS:
Generation of Gas6 deficient mice (Gas6 -/-) was described 4 . All tumor models were performed as described previously 33 . All cell lines were maintained as described 33 . All experimental animal procedures were approved by the Institutional Animal Care and Research Advisory Committee of the K.U. Leuven.
IN VITRO ASSAYS:
Concentrations of Gas6, sAxl and PAI-1 were quantified as described 34 . IL-10 and M-CSF protein levels were determined as recommended (R&D Biosystems, Minneapolis, MN, USA). Quantitative RT-PCR was performed as described 35, 36 , using the probes and primers listed in Supplement Table 1 . Human recombinant Gas6 was produced as described 32 . As already described, human Gas6 binds to murine Axl 8 .
Proliferation was measured using the Cell Proliferation Reagent WST-1 (Roche, Basel, Switzerland 
ISOLATION OF PERITONEAL MACROPHAGES AND STIMULATION WITH CYTOKINES:
Peritoneal macrophages were isolated by flushing the intraperitoneal cavity of 8 weeks old mice with RPMI medium (supplemented with 10% FBS and 1% Penicillin/Streptomycin (Invitrogen)), and allowed to become adherent overnight. Subsequently, they were stimulated for 24h with recombinant VEGF, PlGF, M-CSF, IL-4 or IL-10 (VEGF and PlGF were used at a concentration of 50 ng/ml, all others at 10 ng/ml; all cytokines from R&D).
White blood cells, bone marrow cells, spleen cells, cells from peritoneal and alveolar lavages and from tumors were harvested as described 37, 38 .
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HISTOLOGY, IMMUNOSTAININGS AND MORPHOMETRIC ANALYSES:
All methods for histology and immunostaining have been described 6, 33, 35, 36, 39, 40 . Tumor hypoxia was assessed using pimonidazole and tumor perfusion was analyzed using FITC-conjugated lectin, as described 33, 36 . CORNEA POCKET, HINDLIMB ISCHEMIA AND MYOCARDIAL REVASCULARIZATION: These assays were carried out as described 36 .
BONE MARROW TRANSPLANTATION:
Balb/C and C57/Bl6 WT and Gas6 -/-recipient mice were irradiated with 9 Gy and 9.5 Gy, respectively. Subsequently 5x10 5 
RESULTS
GENERAL REMARK: Supplementary items are preceded by "S" (for instance, Figure S1) 
EXPRESSION OF GAS6 IN THE TUMOR STROMA AND OF TAMRS IN TUMOR CELLS
To elucidate the role of Gas6 in tumor biology, we first studied its expression in different murine tumor cell lines in vitro (CT26 colon, 4T1 breast, TSA breast, PancO2 pancreatic, B16 melanoma). By RT-PCR analysis, none of these tumor lines expressed detectable Gas6 mRNA levels in baseline conditions, nor in hypoxia or serum starvation, i.e. conditions that resemble the tumor microenvironment (not shown). We then tested whether CT26, 4T1 or PancO2 tumors expressed Gas6 mRNA when grown in vivo. In order to dissect the contribution of tumor-versus host-derived Gas6, we compared Gas6 expression in tumors, grown in Gas6 -/-or WT mice. Gas6 mRNA was undetectable in tumors in Gas6 -/-mice, but readily measurable in tumors in WT mice, indicating that Gas6 was produced by host-derived stromal cells ( Figure 1A ; not shown for PancO2 and 4T1).
ELISA measurements confirmed that Gas6 was present in extracts of CT26 and PancO2 tumors in WT mice (52 ± 9.8 pg/mg, not shown for PancO2), but not of tumors in Gas6 
TUMORS EDUCATE INFILTRATED LEUKOCYTES TO PRODUCE GAS6
To further analyze the expression of Gas6 in tumor-infiltrating leukocytes, we FACS sorted CD45 + leukocytes and CD31 + endothelial cells from CT26 tumors, grown in WT mice, and analyzed Gas6 expression by RT-PCR immediately after isolation without further subculturing. These experiments revealed that Gas6 transcript levels were 20-fold higher in leukocytes than in endothelial cells (n=4, p<0.005; Figure 1E ). In contrast to these tumor-infiltrated leukocytes, CD45 + leukocytes that were freshly harvested from the bone marrow (BM) or peripheral blood (PB) of tumor bearing mice, expressed only minimal levels of Gas6 (n=4, p<0.001; Figure 1F ). Also, Gas6 levels were negligible in PB-and BM-derived leukocytes from non-tumor bearing mice (not shown).
Further analysis revealed that Gas6 mRNA levels were abundant in F4/80 + tumorassociated macrophages (TAMs), consistent with the aforementioned immunostaining data ( Figure 1G ). In order to determine whether the tumor microenvironment itself might "educate" TAMs to upregulate Gas6 expression in situ, we FACS-sorted, as controls, resident F4/80 + tissue macrophage populations from the peritoneum, lung and spleen of CT26 tumor-bearing mice and analyzed, by RT-PCR analysis, their Gas6 expression.
These experiments revealed substantially higher Gas6 expression in TAMs than in resident tissue macrophages (n=4/3, p<0,0001; Figure 1G ). These data were confirmed in mice bearing orthotopic PancO2 tumors (not shown). Hence, the tumor microenvironment RT-PCR analysis indicated comparable Gas6 levels in dendritic cells, while a significantly lower production of Gas6 was detectable in all other leukocyte subfractions, with even undetectable Gas6 levels in B cells (n=3; p<0.05; Figure 1H ). As macrophages are more abundant than dendritic cells in CT26 tumors (% of all tumor and stromal cells: 4.8% ± 0.6% versus 0.8% ± 0.2%; p=0.0009; N=4-5), the bulk of Gas6 in the tumor milieu is thus released by TAMs.
GAS6 DEFICIENCY INHIBITS TUMOR GROWTH AND METASTASIS
Given the upregulation of Gas6 in tumor-infiltrating leukocytes, we analyzed the role of Gas6 in tumor growth by using four different syngeneic tumor models in two different genetic backgrounds. In Gas6 -/-mice, the size of endstage subcutaneous CT26 tumors was reduced on average by 38% (n=8-6, p<0.05), while the size of orthotopic 4T1 tumors was decreased by 36% (n=8-7, p<0.05). Likewise, growth of subcutaneous PancO2 tumors was diminished by 39% (n=8-10, p<0.05) and that of orthotopic PancO2 tumors by 55% (n=8-7, p<0.05) ( Because orthotopic 4T1 breast tumors metastasize to the lungs and orthotopic PancO2 tumors spread to mesenteric lymph nodes, we used these models to study the 
GAS6 DEFICIENCY IMPAIRS PROLIFERATION OF TUMOR CELLS IN VIVO
To investigate whether the reduced tumor growth in Gas6 -/-mice was due to showing that recombinant Gas6 dose-dependently increased proliferation of cultured CT26
and 4T1 tumor cell lines ( Figure 3G ; not shown for 4T1), consistent with previous reports 13, 14 . Recombinant sAxl, supplemented in 10-fold molar excess of Gas6, significantly inhibited the mitogenic activity of Gas6 ( Figure 3H ). This effect was specific, as an unrelated sFc-fragment, capturing VEGF (sVEGFR-1/2), failed to significantly inhibit Gas6-induced proliferation of CT26 tumor cells ( Figure 3H ).
GAS6 DEFICIENCY DOES NOT REGULATE TUMOR ANGIOGENESIS OR INFLAMMATION
To assess whether the reduced tumor growth in the absence of stromal Gas6 was attributable to any effects on the tumor stroma, we characterized tumor angiogenesis, a plausible hypothesis, given that Gas6 and its receptors are expressed at low levels in tumor endothelial cells (not shown), and previous studies documented a role for TAMRs in vascular biology [42] [43] [44] . When analyzing CT26 and 4T1 tumor angiogenesis in Gas6 -/-mice in comparison to WT mice, we could, however, not detect any differences in microvessel density or vessel lumen area after staining for CD31 ( Figure S2A ; 4T1 not shown), while tumor vessel perfusion (analyzed after injecting FITC-labeled lectin; Figure S2B ; not shown for 4T1), or tumor hypoxia (analyzed by staining for the hypoxia-marker pimonidazole; Figure S2C ; not shown for 4T1) were also comparable. Furthermore, analysis of tumor vessel maturation, by determining pericyte coverage of vessels via double staining for CD31 and αSMA, did also not reveal significant differences between Gas6 -/-and WT mice ( Figure S2D ; not shown for 4T1). Finally, assessment of necrotic area by morphometric quantification of autofluorescent area revealed no differences either (4T1 and CT26 not shown). Altogether, these results suggest that absence of Gas6 has a negligible impact on tumor angiogenesis. Consistent herewith, we could not detect any differences in pathological angiogenesis in Gas6 -/-mice, as compared with WT control mice, when using additional angiogenesis models, including the cornea pocket assay, or the hindlimb ischemia or coronary artery ligation assays ( Figure S3A-E) . In 4T1 tumors grown in Gas6 -/-mice, no differences in lymphatic vessel area or density could be detected either ( Figure S3F ; density not shown).
Given that TAMRs are expressed by leukocytes 10 , we also analyzed leukocyte infiltration in CT26, 4T1 and PancO2 tumors, but could not detect any genotypic differences in the number of CD45 + cells inside tumors ( Figure S3G ; not shown for 4T1
and PancO2). In addition, there were no significant genotypic differences in TAMR expression in CD45 + tumor-infiltrating leukocytes or F4/80 + macrophages (not shown).
Furthermore, morphometric quantification of the number of vimentin + cells revealed no genotypic differences in the accumulation of cancer-associated fibroblasts (CAFs) in CT26
and 4T1 tumors ( Figure S3H ; not shown for 4T1). Because Gas6 has been implicated in thrombus stabilization 4 , we also investigated different parameters of coagulation in tumorbearing WT and Gas6 -/-mice. Analysis of the prothrombin time and the activated partial thromboplastin time, as well as measurement of plasma levels of the plasminogenactivator inhibitor-1 (PAI-1) or intratumoral levels of fibrin(ogen) + or von Willebrand factor (vWF) + thrombi showed, however, no genotypic differences, rendering it unlikely that Gas6 deficiency influenced intra-tumoral coagulation substantially ( Figure S4A -E).
TRANSPLANTATION OF WT BONE MARROW RESCUES TUMOR GROWTH IN GAS6 -/-MICE
To further explore whether the reduced tumor growth in Gas6 -/-mice was attributable to the lack of Gas6 expression by tumor-infiltrating leukocytes, we transplanted WT bone marrow of syngeneic mice, ubiquitously expressing GFP, in lethally irradiated 
Gas6
-/-bone marrow in Gas6 -/-hosts (KO→KO mice) was used as positive and negative control, respectively. Six weeks after bone marrow transplantation (BMT), when CT26 colon tumors were injected subcutaneously, hematopoietic reconstitution and differential blood counts were comparable in all genotypes (not shown).
Growth of CT26 tumors in WT→WT mice was slower than tumor growth in WT hosts without BMT and, similarly, CT26 tumor growth was slower in KO→KO mice than in To correlate Gas6 expression by infiltrating leukocytes with tumor growth, we also measured, by RT-PCR analysis, Gas6 expression in CT26 tumors of the aforementioned chimeric mouse models. This analysis revealed that tumor Gas6 mRNA levels, which were undetectable in KO→KO mice, were rescued in WT→KO mice to levels, nearly approaching those found in WT→WT mice ( Figure 4D ). Conversely, in KO→WT mice, Gas6 mRNA levels were very low ( Figure 4D ). This low Gas6 expression in CT26 tumors in KO→WT mice was, however, not due to the infiltration of fewer infiltrating leukocytes, Figure S3G with Figure S5C ). Also, expression of Axl, Tyro3 and Mer was comparable in tumors grown in WT→WT and in WT→KO mice ( Figure 4E ). These findings underline that bone marrow-derived 
IL-10 AND M-CSF UPREGULATE GAS6 IN MACROPHAGES
Finally, in an initial effort to start elucidating how tumors educate infiltrating leukocytes to upregulate Gas6, we analyzed a panel of possible molecular candidates that might regulate Gas6 expression in differentiated macrophages. We therefore isolated peritoneal macrophages and incubated them with different cytokines, known to be For . Indeed, Gas6 induces proliferation of mammary carcinoma cells 56 , melanoma cells 14 and prostate cancer cells 13 .
Previous studies documented that Gas6 often acts in a paracrine manner on tumor cells, though autocrine production and effects have also been reported 13, 21 . Expression The enhanced production of Gas6 by bone marrow-derived leukocytes, upon infiltration in the tumor micro-environment, contributes to the growth of the primary tumor and metastasis. Indeed, replacement of Gas6 -/-bone marrow by WT bone marrow not only rescued the impaired tumor growth in Gas6 -/-mice, but also largely restored intra-tumoral Gas6 levels to WT levels, without, however, inducing any change in leukocyte recruitment. However, none of these previous studies analyzed the endogenous role of Gas6 in health and disease in vivo. One, perhaps the most straightforward, explanation for these discrepant observations is that endogenous Gas6 is redundant or has a negligible effect in
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